Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS
· Delayed Price · Currency is USD
0.120
0.00 (0.00%)
At close: Apr 29, 2026
Eloxx Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
608.63K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emmaus Life Sciences | 12.45M |
| SQZ Biotechnologies Company | 12.12M |
| Halberd | 6.94K |
| EV Biologics | 9.47M |
| Aibotics | 2.18K |
| Sorrento Therapeutics | 64.27M |
| Regenerative Medical Technology Group | 5.04M |
| Iterum Therapeutics | 390.00K |
Eloxx Pharmaceuticals News
- 1 year ago - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases - Business Wire
- 2 years ago - Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome - GlobeNewsWire